{"nctId":"NCT04161495","briefTitle":"A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","startDateStruct":{"date":"2019-11-19","type":"ACTUAL"},"conditions":["Factor VIII Deficiency"],"count":159,"armGroups":[{"label":"Arm A: Prophylaxis","type":"EXPERIMENTAL","interventionNames":["Biological: efanesoctocog alfa (BIVV001)"]},{"label":"Arm B: On-Demand Then Prophylaxis","type":"EXPERIMENTAL","interventionNames":["Biological: efanesoctocog alfa (BIVV001)"]}],"interventions":[{"name":"efanesoctocog alfa (BIVV001)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Participant, male or female, must be equal to or greater than 12 years of age inclusive, at the time of signing the informed consent.\n* Severe hemophilia A, defined as less than (\\<) 1 international units per deciliter (IU/dL) (\\<1 percent \\[%\\]) endogenous FVIII activity as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating \\<1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A.\n* Previous treatment for hemophilia A (prophylaxis or on demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 exposure days.\n* Current regimen included one of the following:\n\n  * Prophylactic treatment regimen with a FVIII product or prophylactic emicizumab therapy for at least 6 months during the previous 12 months. Appropriate washout time needs to be taken into account.\n  * On-demand regimen with a FVIII product with a history of at least 12 bleeding episodes in the previous 12 months or at least 6 bleeding episodes in the previous 6 months prior to study enrollment.\n* On-demand participant was accepted to move to a prophylaxis treatment regimen after 26-week on-demand period.\n* Willingness and ability of the participant or surrogate (a caregiver or a family member greater than or equal to \\[\\>=\\] 18 years of age) to complete training in the use of the study electronic Patient Diary (ePD) and to use the ePD throughout the study.\n* Ability of the participant or his or her legally authorized representative (eg., parent or legal guardian) to understand the purpose and risks of the study, willing and able to comply with study requirements and provide signed and dated informed consent or assent (as applicable) and authorization to use protected health information in accordance with national and local participant privacy regulations.\n\nExclusion criteria:\n\n* Clinically significant liver disease.\n* Serious active bacterial or viral infection (other than chronic hepatitis or HIV) present within 30 days of screening.\n* Other known coagulation disorder(s) in addition to hemophilia A.\n* History of hypersensitivity or anaphylaxis associated with any FVIII product.\n* Positive inhibitor results, defined as \\>=0.6 Bethesda unit per milliliter (BU/mL) at screening. History of a positive inhibitor test defined as \\>=0.6 BU/mL. Family history of inhibitors would not exclude the participant.\n* Use of Emicizumab within the 20 weeks prior to screening.\n* Major surgery within 8 weeks prior to screening.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Estimated Annualized Bleeding Rate (ABR) in Arm A: Prophylaxis","description":"ABR is annualized number of treated bleeding episodes (BE) per participant per year. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BIVV001. It started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered less than or equal to (\\<=) 72 hours apart from previous injection were considered same bleeding episode. ABR=number of treated BE during efficacy period (EP)/number of days during EP\\*365.25. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to the study arms and treatment regimens. This outcome measure (OM) presents estimated results (i.e., results estimated by fitting negative binomial \\[NB\\] regression model on data collected during EP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null}]}]}]},{"type":"PRIMARY","title":"Observed Annualized Bleeding Rate in Arm A: Prophylaxis","description":"ABR is annualized number of treated bleeding episodes per participant per year. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BIVV001. It started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. ABR=number of treated bleeding episodes during EP/number of days during EP\\*365.25. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to the study arms and treatment regimens. This OM presents observed results (i.e., descriptive statistics values based on the data which was collected during EP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"1.43"}]}]}]},{"type":"SECONDARY","title":"Estimated Annualized Bleeding Rate During the Efficacy Period in Arm A: Prophylaxis - Non-inferiority Analysis","description":"ABR is annualized number of treated bleeding episodes per participant per year. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BIVV001. It started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. ABR=number of treated bleeding episodes during EP/number of days during EP\\*365.25. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to the study arms and treatment regimens. This OM presents estimated results (i.e., results received estimated by fitting NB regression model on data collected during EP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.99","spread":null},{"groupId":"OG001","value":"0.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Annualized Bleeding Rate During the Efficacy Period in Prophylaxis - Non-inferiority Analysis","description":"ABR is annualized number of treated bleeding episodes per participant per year. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BIVV001. It started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. ABR=number of treated bleeding episodes during EP/number of days during EP\\*365.25. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to the study arms and treatment regimens. This OM presents observed results (i.e., descriptive statistics values based on the data which was collected during EP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":"5.21"},{"groupId":"OG001","value":"0.69","spread":"1.51"}]}]}]},{"type":"SECONDARY","title":"Estimated Annualized Bleeding Rate During the Efficacy Period in Arm A: Prophylaxis - Superiority Analysis","description":"ABR is annualized number of treated bleeding episodes per participant per year. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BIVV001. It started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. ABR=number of treated bleeding episodes during EP/number of days during EP\\*365.25. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to the study arms and treatment regimens. This OM presents estimated results (i.e., results received estimated by fitting NB regression model on data collected during EP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.96","spread":null},{"groupId":"OG001","value":"0.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Annualized Bleeding Rate During the Efficacy Period in Arm A: Prophylaxis - Superiority Analysis","description":"ABR is annualized number of treated bleeding episodes per participant per year. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BIVV001. It started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. ABR=number of treated bleeding episodes during EP/number of days during EP\\*365.25. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to the study arms and treatment regimens. This OM presents observed results (i.e., descriptive statistics values based on the data which was collected during EP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.95","spread":"5.19"},{"groupId":"OG001","value":"0.68","spread":"1.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemophilia-specific Health-related Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Domain Score at Week 52 in Arm A: Prophylaxis","description":"Haem-A-QoL is a participant-reported questionnaire designed for adult participants (greater than or equal to \\[\\>=\\] 17 years of age) with hemophilia; and consisted of 46 items comprising 10 domains (physical health \\[5 items\\], feelings \\[4 items\\], view of self \\[5 items\\], sports and leisure \\[5 items\\], work and school \\[4 items\\], dealing with hemophilia \\[3 items\\], treatment \\[8 items\\], future \\[5 items\\], family planning \\[4 items\\], partnership and sexuality \\[3 items\\]). Items were rated along five response options: never, rarely, sometimes, often, or all the time. Raw score for physical health domain were transformed to a scale ranged from 0 to 100, where lower scores denoted better physical health. Change from baseline in physical Health domain score was reported in this OM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.79","spread":"18.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pain Intensity 3a Score at Week 52 in Arm A: Prophylaxis","description":"PROMIS is a system of reliable and precise measures of participant-reported heath status. PROMIS measures cover physical, mental and social health and can be used for many chronic conditions. PROMIS - Pain Intensity - Short Form 3a consisted of 3 questions, participants reported for the intensity of pain experienced in the past 7 days. Each question had 5 responses scored between 1 (had no pain) to 5 (very severe pain). Total PROMIS pain intensity 3a score range was from 3 (no pain) to 15 (very severe pain), where higher score indicated more intense pain. Total raw score was converted into a T-score which rescaled raw score into standardized score with mean of 50 and standard deviation (SD) of 10. Higher PROMIS T-score represented worst outcome. For PROMIS pain intensity 3a, T-score of 60 was one SD worse than average.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.97","spread":"7.86"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemophilia Joint Health Score (HJHS) Total Score at Week 52 in Arm A: Prophylaxis","description":"HJHS is a validated 11-item scoring tool developed for the assessment of joint health in participants with hemophilia. It comprised an evaluation of the elbows, knee and ankle joints: swelling (0 to 3), duration of swelling (0 and 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2) and strength (0 to 4), in each item 0 = none and higher score = severe damage and global gait (walking, stairs, running, hopping on 1 leg) scored on scale ranged from 0 to 4, where 0 = all skills in normal limit and 4 = no skills within normal limits). Total HJHS score = sum of joint totals (0 to 120) + general gait (1 to 4) and ranged from 0 (no joint damage) to 124 (severe joint damage), where higher score indicated severe joint damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"6.4"}]}]}]},{"type":"SECONDARY","title":"Annualized Bleeding Rate by Type of Bleed (Spontaneous, Traumatic and Unknown Type)","description":"ABR: annualized number of treated bleeding episodes per participant per year. EP reflects sum of all intervals of time during which participants were treated with BIVV001 according to study arms and treatment regimens. Treated bleeding episode: episode that started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. Any bleed at different location was considered as separate bleeding episode, regardless of time from last injection. Spontaneous bleeding: bleeding episode without contributing factor (definite trauma/antecedent \"strenuous\" activity). Traumatic bleeding: bleeding episode with known/believed reason for bleed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"16.69","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"3.95","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Bleeding Rate by Location of Bleed (Joint, Muscle, Internal and Skin/Mucosa)","description":"ABR: annualized number of treated bleeding episodes per participant per year. Efficacy period reflects sum of all intervals of time during which participants were treated with BIVV001 according to study arms and treatment regimens. Treated bleeding episode: episode that started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. Any bleed at different location was considered as separate bleeding episode, regardless of time from last injection. Spontaneous bleeding: bleeding episode without contributing factor (definite trauma/antecedent \"strenuous\" activity). Traumatic bleeding: bleeding episode with known/believed reason for bleed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"18.42","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Bleeding Rate for All Bleeding Episodes","description":"ABR: annualized number of all bleeding (treated and untreated) episodes/participant/year. ABR = number of all bleeding episodes during EP/number of days in EP\\*365.25. EP reflects sum of all time intervals during which participants were treated with BIVV001 according to study arms and treatment regimens. Bleeding episode: episode started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. Any bleed at different location: considered as separate bleeding episode, regardless of time from last injection. Spontaneous: bleeding without contributing factor (definite trauma/antecedent \"strenuous\" activity). Traumatic: bleeding with known/believed reason.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"21.13","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Bleeding Rate: Intra-participant Comparison of Arm B Participants","description":"ABR is annualized number of treated bleeding episodes per participant per year. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BIVV001. It started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location/injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. ABR = (Number of treated bleeding episodes during EP/number of days during EP\\*365.25. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to the study arms and treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.13","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Factor VIII (FVIII) Activity Levels Above 1%, 5%, 10%, 15%, and 20% in Arm A: Prophylaxis","description":"FVIII activity level was measured using activated partial thromboplastin time (aPTT)-based one stage clotting assay. Percentage of participants who achieved steady-state trough FVIII activity levels above (\\>) 1%, 5%, 10%, 15%, and 20% were reported for Arm A: Prophylaxis in this OM. Participants were counted in more than one row, as applicable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Injections of BIVV001 Required to Treat a Bleeding Episode","description":"The number of injections required to resolve each bleeding episode was averaged across all bleeding episodes per participant. A bleeding episode was defined as an episode that started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location or injections administered \\<=72 hours apart from previous injection were considered same bleeding episode.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Dose of BIVV001 Required to Treat Bleeding Episode","description":"The total dose (IU/kg) used to resolve each bleeding episode was averaged across all bleeding episodes per participant. A bleeding episode was defined as an episode that started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location or injections administered \\<=72 hours apart from previous injection were considered same bleeding episode.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.85","spread":null},{"groupId":"OG001","value":"50.96","spread":null},{"groupId":"OG002","value":"49.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Bleeding Episodes Treated With a Single Injection of BIVV001","description":"A bleeding episode was defined as an episode that started from 1st sign of bleed and ended no more than 72 hours after last injection to treat bleeding episode, any subsequent bleeding at same location or injections administered \\<=72 hours apart from previous injection were considered same bleeding episode. Percentage of bleeding episodes (of all bleeding episodes occurred) which were treated with single injection was reported in this OM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"97.4","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Response to BIVV001 Treatment Based on the International Society on Thrombosis and Haemostasis (ISTH) 4-point Response Scale","description":"The participant's response related to each injection of BIVV001 treatment for treating a bleed was evaluated using ISTH 4-point response scale categorized as: Excellent (complete pain relief/complete resolution of signs of bleeding), Good (significant pain relief/improvement in signs of bleeding), Moderate (modest pain relief/improvement in signs of bleeding) and none (no or minimal improvement/condition worsened). Assessment was performed approximately 72 hours after the initial treatment for the bleeding episode. Bleeding episode was defined as an episode that started from first sign of a bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at same location or injections \\<=72 hours apart were considered same bleeding episode. Participants were counted in more than one row, as applicable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","spread":null},{"groupId":"OG001","value":"98.4","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"76.5","spread":null},{"groupId":"OG002","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":null},{"groupId":"OG001","value":"22.0","spread":null},{"groupId":"OG002","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Physicians' Global Assessment of Participant's Response to BIVV001 Treatment","description":"Physicians assessed participant's response to BIVV001 treatment using 4-point response scale: Excellent=bleeding episodes (BE) responded to fewer than/usual number of injections/less than/usual dose of FVIII/rate of breakthrough bleeding during prophylaxis was \\<= that usually observed; Effective = most BE responded to same number of injections and dose, but some required more injections/higher doses/there was minor increase in rate of breakthrough bleeding; partially effective = BE most often required more injections and/or higher doses than expected/adequate breakthrough bleeding prevention during prophylaxis required more frequent injections and/or higher doses; Ineffective = routine failure to control hemostasis or hemostatic control required additional agents. Percentages were based on total number of responses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null},{"groupId":"OG001","value":"96.1","spread":null},{"groupId":"OG002","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Annualized BIVV001 Consumption Per Participant","description":"Total annualized BIVV001 consumption (in IU/kg) was calculated for each participant as: Total IU/kg of BIVV001 during EP divided by total number of days during EP\\*365.25. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to the study arms and treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2756.99","spread":null},{"groupId":"OG001","value":"1212.27","spread":null},{"groupId":"OG002","value":"2737.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemophilia Joint Health Score (HJHS) Domain Score at Week 52 in Arm A: Prophylaxis","description":"HJHS is a validated 11-item scoring tool developed for the assessment of joint health in participants with hemophilia. Following domains were assessed for elbows, knee and ankle joints: swelling (score 0 = no swelling to 3=severe), duration of swelling (score 0 = no swelling and 1 = \\>=6 months), muscle atrophy (score 0 = none to 2 = severe), crepitus on motion (score 0 = none to 2=severe), flexion loss (score 0 = \\<5' to 3 = \\>20'), extension loss (score 0 = \\<5' to 3 = \\>20'), joint pain (score 0 = no pain through active range of motion to 2 = pain through active range) and strength (score 0 = holds test position with maximum resistance to 4 = trace/no muscle contraction), in each item 0 = none and higher score = severe damage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Estimated Annualized Joint Bleeding Rate (AJBR)","description":"AJBR: annualized number of joint bleeding/participant/year. ABR = number of treated joint bleeding episodes during EP divided by total number of days during EP\\*365.25. Joint bleeding episode: an unusual sensation in joint ('aura') in combination with 1) increasing swelling/warmth over skin, joint; 2) increasing pain or 3) progressive loss of range of motion or difficulty in using limb as compared with Baseline. Bleeding episode (BE): episode that started from first sign of bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at same location/injections \\<=72 hours apart were considered same bleeding episode. EP reflects the sum of all intervals of time during which participants were treated with BIVV001 according to study arms and treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":null},{"groupId":"OG001","value":"17.48","spread":null},{"groupId":"OG002","value":"0.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Annualized Joint Bleeding Rate (AJBR)","description":"AJBR: annualized number of joint bleeding/participant/year. ABR = number of treated joint bleeding episodes during EP divided by total number of days during EP\\*365.25. Joint bleeding episode: unusual sensation in joint ('aura') with 1) in combination with increasing swelling/warmth over skin, joint; 2) increasing pain or 3) progressive loss of range of motion or difficulty in using limb as compared with Baseline. BE: episode that started from first sign of bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at same location/injections \\<= 72 hours apart were considered same bleeding episode. EP reflects sum of all intervals of time during which participants were treated with BIVV001 according to study arms and treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"1.09"},{"groupId":"OG001","value":"17.45","spread":"7.31"},{"groupId":"OG002","value":"0.61","spread":"1.33"}]}]}]},{"type":"SECONDARY","title":"Total Number of Target Joint Resolved in Participants at Week 52 in Arm A: Prophylaxis","description":"A target joint at baseline was defined as a major joint with \\>=3 spontaneous bleeding episodes in a consecutive 6 month period prior to entry to the study, captured at Baseline. A target joint resolved was defined as \\<=2 spontaneous bleeds into that joint during 12 months of continuous exposure. Total number of target joints resolved at Week 52 were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemophilia-specific Health-related Quality of Life Questionnaire for Adults Total Score at Week 52 in Arm A: Prophylaxis","description":"Haem-A-QoL: participant-reported questionnaire designed for adult participants (\\>=17 years of age) with hemophilia; and consisted of 46 items comprising 10 domains (physical health \\[5 items\\], feelings \\[4 items\\], view of self \\[5 items\\], sports and leisure \\[5 items\\], work and school \\[4 items\\], dealing with hemophilia \\[3 items\\], treatment \\[8 items\\], future \\[5 items\\], family planning \\[4 items\\], partnership and sexuality \\[3 items\\]). Items were rated along 5 response options: 1=never, 2=rarely, 3=sometimes,4=often, and 5=all the time and higher scores represent greater impairment. Raw score for each domain were transformed to a scale ranged between 0 and 100, where lower scores denoted better physical health. Haem-A-QoL Total Score was average of all domain scores and ranged from 0 to 100, where lower scores = better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.56","spread":"11.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Reported Outcomes Measurements Information Systems Short Form (PROMIS-SF) Physical Function (PF) 6b at Week 52 in Arm A: Prophylaxis","description":"PROMIS-SF v2.0 PF 6b consisted of 2-items from item-improved Health Assessment Questionnaire (HAQ) and 4-items from item-improved Physical Function-10 (PF-10) instruments. Both of these instruments assessed participant's present abilities and had 5-response options: HAQ: 1=without any difficulty, 2=with little difficulty, 3=with some difficulty, 4=with much difficulty,5=unable to do and PF-10: 1=not at all, 2=very little, 3=somewhat, 4=quite a lot, 5=cannot do. Total score of PROMIS-SF PF 6b: average scores of component items, which ranged from 0 (no disability) to 100 (worst disability). T-score rescales raw scale score (sum of scores from all questions answered) into a standardized score with a mean of 50 and standard deviation of 10, based on scoring tables provided in PROMIS Scoring Manuals. Higher PROMIS T-score=more of concept being measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":"4.77"}]}]}]},{"type":"SECONDARY","title":"Investigators' or Surgeons' Assessment of Participant's Hemostatic Response to BIVV001 Treatment","description":"The Investigators/Surgeons who complete the surgical procedures assess the participant's response to surgery with BIVV001 treatment using a 4-point scale, where responses were categorized as worst response: 1 = Excellent, 2 = Good, 3 = Fair, and 4 = Poor/none. Higher score indicated worst response. This assessment was performed 24 hours after the surgery. A surgery can be counted in more than one response category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Injections Per Surgery Required to Maintain Hemostasis During Perioperative Period for Major Surgery","description":"Perioperative period was time lapse surrounding the surgical act which was divided into 3 stages: preoperative (4 weeks prior to surgery), operative (during the surgery) and post-operative (24-hour post-surgery). The number of injections to maintain hemostasis (a process to prevent and stop bleeding from a blood vessel) per surgery included all injections from loading dose (i.e., the preoperative injection, administered either on the day of surgery or one day prior to the surgery), to the end of surgery. Major surgery: defined as any invasive operative procedure that required any of the following: opening into major body cavity (e.g., abdomen, thorax, skull); operation on a joint; removal of an organ; dental extraction of any molar teeth or \\>=3 non-molar teeth; operative alteration of normal anatomy; crossing of a mesenchymal barrier (e.g., pleura, peritoneum, dura).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Dose Required to Maintain Hemostasis From Day -1 to Day 0 During Perioperative Period for Major Surgery","description":"Perioperative period was time lapse surrounding surgical act which was divided into 3 stages: preoperative (4 weeks prior to surgery), operative (during the surgery) and post-operative (24-hour post-surgery). Total dose (IU/kg) was the sum across all injections per major surgery (including loading dose) needed to maintain hemostasis (a process to prevent and stop bleeding from a blood vessel) during surgery. Major surgery: defined as any invasive operative procedure that required any of the following: opening into major body cavity (e.g., abdomen, thorax, skull); operation on a joint; removal of an organ; dental extraction of any molar teeth or \\>=3 non-molar teeth; operative alteration of normal anatomy; crossing of a mesenchymal barrier (e.g., pleura, peritoneum, dura). Day 0 was defined as the surgery day. The loading dose for a given surgery was the preoperative injection, administered either on the day of surgery or one day prior to the surgery (i.e., Day -1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.65","spread":"15.21"}]}]}]},{"type":"SECONDARY","title":"Total BIVV001 Consumption From Day -1 to 14 During Perioperative Period for Major Surgery","description":"Perioperative period: time lapse surrounding surgical act which was divided into 3 stages: preoperative (4 weeks prior to surgery), operative (during the surgery) and post-operative (24-hour post-surgery). Total BIVV001 consumption were summarized from the loading dose (the day before surgery, i.e, on Day -1) up to 2 weeks following the surgery (i.e., Day 14) and were reported in this OM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"166.71","spread":"72.48"}]}]}]},{"type":"SECONDARY","title":"Number of Blood Component Transfusions Used During Perioperative Period for Major Surgery","description":"The perioperative period was the time lapse surrounding the surgical act which was divided into 3 stages: preoperative (4 weeks prior to surgery), operative (during the surgery) and post-operative (24-hour post-surgery). The number of blood component transfusions used during perioperative period were summarized categorically (0, 1, 2, 3 and \\>3) for all major surgeries for the surgery subgroup. Major surgery: defined as any invasive operative procedure that required any of the following: opening into major body cavity (e.g., abdomen, thorax, skull); operation on a joint; removal of an organ; dental extraction of any molar teeth or \\>=3 non-molar teeth; operative alteration of normal anatomy; crossing of a mesenchymal barrier (e.g., pleura, peritoneum, dura).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Type of Blood Component Transfusions Used During Perioperative Period for Major Surgery","description":"The perioperative period was the time lapse surrounding the surgical act which was divided into 3 stages: preoperative (4 weeks prior to surgery), operative (during the surgery) and post-operative (24-hour post-surgery). The type of blood component (Red blood cell, platelet, fresh frozen plasma, whole blood and other) transfusions used were summarized for all major surgeries. Post-operative referred to the day following the end of surgery to the date of hospital discharge. Major surgery: defined as any invasive operative procedure that required any of the following: opening into major body cavity (e.g., abdomen, thorax, skull); operation on a joint; removal of an organ; dental extraction of any molar teeth or \\>=3 non-molar teeth; operative alteration of normal anatomy; crossing of a mesenchymal barrier (e.g., pleura, peritoneum, dura).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Blood Loss During Major Surgery","description":"The estimated total blood loss (in milliliters) during major surgeries were summarized. Major surgery: defined as any invasive operative procedure that required any of the following: opening into major body cavity (e.g., abdomen, thorax, skull); operation on a joint; removal of an organ; dental extraction of any molar teeth or \\>=3 non-molar teeth; operative alteration of normal anatomy; crossing of a mesenchymal barrier (e.g., pleura, peritoneum, dura).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143.33","spread":"189.38"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)","description":"An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug which did not necessarily have a causal relationship with the treatment. A serious AE (SAE) was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was a medically important event. Treatment-emergent AEs were AEs that developed, worsened or became serious from Baseline (Day 1) up to 3 weeks post last dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Neutralizing Antibodies (Development of Inhibitors) Directed Against Factor VIII","description":"Development of inhibitors was defined as an inhibitor result of \\>=0.6 bethesda unit per milliliter (BU/mL) that was confirmed by a second test result of \\>=0.6 BU/mL from a separate sample, drawn 2 to 4 weeks following the date when the original sample was drawn. Both tests must have been performed by the central laboratory using the Nijmegen-modified Bethesda assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Occurrence of Embolic and Thrombotic Events","description":"Embolic and thrombotic events were defined as arterial or venous thrombosis, confirmed by imaging.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Maximum FVIII Activity (Cmax)","description":"Cmax was defined as the maximum observed plasma FVIII Activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.05","spread":"31.72"},{"groupId":"OG001","value":"138.36","spread":"48.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144.72","spread":"36.65"},{"groupId":"OG001","value":"149.42","spread":"29.63"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Elimination Half-life (t1/2z)","description":"Plasma t1/2z was the time measured for the plasma concentration of drug to decrease by one half. Only for participants who were enrolled in sequential PK subgroup of study, PK samples were collected for all timepoints at Baseline and at Week 26; however, participants did not receive BIVV001 dose in week 2 and week 27.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Clearance (CL)","description":"CL is defined as the rate at which the drug is removed from the body. Only for participants who were enrolled in sequential PK subgroup of study, PK samples were collected for all timepoints at Baseline; however, participants did not receive BIVV001 dose in week 2 and week 27.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.508","spread":"0.124"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Total Clearance at Steady State (CLss)","description":"CLss is defined as the rate at which the drug is removed from the body at steady state. Only for participants who were enrolled in sequential PK subgroup of study, PK samples were collected for all timepoints at Week 26; however, participants did not receive BIVV001 dose in week 2 and week 27.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.449","spread":"0.101"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Accumulation Index (AI)","description":"AI is the ratio of accumulation of a drug under steady state conditions (i.e., after repeated administration) as compared to a single dose. AI was calculated as ratio of area under the curve (AUC) at Week 26 (Day 183) divided by AUC at Day 1, where AUC is the area under the plasma concentration versus time curve from time 0 to infinity. Only for participants who were enrolled in sequential PK subgroup of study, PK samples were collected for all timepoints at Week 26; however, participants did not receive BIVV001 dose in week 2 and week 27.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"0.160"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Plasma FVIII Activity Versus Time Curve (AUC0-tau)","description":"AUC0-tau was defined as area under the plasma concentration-time profile from time zero (pre-dose) to dosing interval. Only for participants who were enrolled in sequential PK subgroup of study, PK samples were collected for all timepoints at Baseline and at Week 26; however, participants did not receive BIVV001 dose in week 2 and week 27.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9600","spread":"2010"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11800","spread":"2720"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Volume of Distribution at Steady State (Vss)","description":"Volume of distribution (Vd) is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss is the apparent volume of distribution at steady-state. Only for participants who were enrolled in sequential PK subgroup of study, PK samples were collected for all timepoints at Baseline and at Week 26; however, participants did not receive BIVV001 dose in week 2 and week 27.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":"7.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":"8.26"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Mean Residence Time (MRT)","description":"MRT is the average total time a drug molecule spends in the body. Only for participants who were enrolled in sequential PK subgroup of study, PK samples were collected for all timepoints at Baseline and at Week 26; however, participants did not receive BIVV001 dose in week 2 and week 27.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Incremental Recovery (IR)","description":"IR was calculated as (Peak activity \\[in IU/dL\\] - Trough activity \\[in IU/dL\\])/Actual Dose (in IU/kg), and peak activity at each visit was the highest activity level after the dosing, and trough activity at each visit was the activity level prior to the dosing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":"0.648"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.05","spread":"0.592"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Trough Concentration for BIVV001 (Ctrough)","description":"Ctrough is the pre-dose concentration of a drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.70","spread":"10.72"},{"groupId":"OG001","value":"21.14","spread":"29.59"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Time Above Predefined (10 and 40%) FVIII Activity Levels","description":"Time above predefined (10 and 40%) FVIII activity levels mean time which BIVV001 maintains above 10 IU/dL and 40 IU/dL with single dose of 50 IU/kg. Only for participants who were enrolled in sequential PK subgroup of study, PK samples were collected for all timepoints at Baseline; however, participants did not receive BIVV001 dose in week 2 and week 27.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":133},"commonTop":["Headache","Arthralgia","Fall","Back Pain","Fatigue"]}}}